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ABSTRACT
The applications of carbon nanomaterials (CNM), including graphene and its
derivatives such as carbon nanotubes (CNTs) in nanomedicine is well established.
These nanomaterials have been widely used as theranostic delivery systems with the
potential to deliver bioactive agents and simultaneously detect selectively diseased
tissues. A rather underexplored CNM for biomedical imaging and theranostics delivery
are carbon nano-onions (CNOs). CNOs are carbon-based nanomaterials that can
potentially be used in cancer therapy when they are functionalized. Recent studies on
cellular fate of different CNMs, including CNOs, have demonstrated that the surface
composition is critical for the in vivo application of these CNM. Current research
discusses the preparation and characterization a novel CNO-Pt nanomaterial and the
cell viability of U87 glioblastoma cells in the presence of this functionalized CNO. In
order to form the desired CNO-Pt compound, the CNOs were first oxidized, followed by
attachment of the cis-diammine platinum(II) dichloride. The novel CNO-Pt nanomaterial
was characterized by IR and UV-Vis spectroscopies. Cytotoxicity of the material was
tested on U87 glioblastoma cells. Following an Alamar Blue assay, the CNO-Pt material
showed approximately 25% cell death at all concentrations after only 24 hours.

THERANOSTICS AND NANOMEDICINE WITH CARBON NANOMATERIALS
Theranostics and Nanomedicine
The field of medicine is constantly changing and evolving as new discoveries are
made and technology becomes more advanced. Theranostics is an emerging field of
medicine which combines therapeutics and diagnostics in an effort to both diagnose and
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treat simultaneously (1). The use of nanomedicine is very important in the theranostic
field as well. Nanomedicine can be defined as the medical application of
nanotechnology. Nanotechnology can help medications to be delivered more directly to
the target area and have less of an effect on the body as a whole, which is especially
important in cancer therapy. Current chemotherapy has a major effect on the whole
body, killing healthy cells as well as cancerous cells. Nanomedicine can help direct the
drug directly to the tumor and decrease exposure throughout the body, eliminating
some of the harsh side effects that are present with current treatments (2). This type of
treatment allows for movement towards personalized medicine, which is the process of
diagnosing, monitoring, and treating patients in a way that will best fit their exact
personal needs. This would be much more effective for decreasing the tumor size, as
well as give the patient a much better quality of life.
Utilizing nanomedicine can also reduce the frequency of taking medications. The
body can typically remove medicines rapidly, but nanoparticles can be retained and
continue to release a drug over a more extended period of time (3). Many nanoparticles
have major advantages that make them great theranostic delivery agents. Several
carbon nanomaterials have begun to show promise in the field of theranostics and they
are the subjects of much ongoing research.
Carbon Nanomaterials
Carbon nanomaterials (CNMs) have recently become a very popular subject of
chemistry research. They have many potential applications in bioimaging and
theranostic delivery, but their poor solubility in some common solvents hinders some of
their potential for use. Some CNMs can be functionalized to increase their solubility,
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therefore increasing their potential for biological application. Many different types of
carbon nanomaterials can be explored for this purpose.
Carbon nanotubes (CNTs) (Figure 1) are a type of CNM that resemble a hollow
cylinder. CNTs can be formed by rolling up sheets of graphenes, or single layers of
carbon atoms, into a tube-like shape. Nanotubes are now known to be one of the most
stable carbon aggregates. CNTs can be single-walled (SWNT) or multi-walled (MWNT)
depending on the number of graphene shells. SWNTs are longer tubes that are formed
from the wrapping of a single sheet of graphene into a cylindrical shape. The sidewalls
of the cylinders can be rolled in different ways to give specific nanotubes unique
characteristics. MWNTs are made up of concentric SWNTs, giving them distinct
properties compared to SWNTs.

Figure 1. Structure of a carbon nanotube (4).
SWNTs have shown to be better for drug delivery than MWNTs because of their
one-dimensional structure and very large surface area. Also, research has shown that
anticancer drugs circulate much longer in the blood when attached to a SWNT than it
does on its own. This allows for continuous uptake of the drug by a tumor for a
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prolonged period of time, which is important in helping treat cancer more effectively.
MWNTs tend to be more useful for thermal cancer treatment such as radiation. After
being exposed to wavelengths of near infrared light, MWNTs release much vibrational
energy into the tissue. This release of energy causes heating in the local area which
can destroy cancer cells (5). Therefore, both types of nanotubes have much therapeutic
potential.
Carbon nanotubes were discovered to have impressive chemical, electrical,
thermal and mechanical properties that other carbon materials lack. They are also low
in cytotoxicity, making them suitable for biological use. The chemical properties and
great surface area of CNTs allow for modification of the surface of their outer shells,
including the attachment of many functional groups. The surface can be functionalized
to make them more water soluble, as well as to attach drug molecules. The structure
and properties of the nanotubes could allow an attached drug to be released to a cell
and enter via endocytosis or even passive diffusion (4). This makes CNTs seem very
promising as delivery vehicles and gives them much potential for use in cancer therapy.
Drugs are not the only molecules that can be added to the surface of CNTs.
Fluorescent materials can also be attached to nanotubes, allowing them to be used for
imaging purposes as well (5). The therapeutic application along with their imaging
abilities and low cytotoxicity make carbon nanotubes very desirable in the growing field
of theranostics.
Carbon nanohorns (CNHs), sometimes called carbon nanocones (Figure 2), are
a conically shaped type of CNM. They are very similar to nanotubes, but with closed
ends. Nanohorns, like nanotubes, can be single-layered or multi-layered with each
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having different properties. CNHs are very chemically stable, have high purity and low
cytotoxicity along with great catalytic properties and good conductivity. These properties
give CNHs a wide range of uses, including many biomedical applications. They have
much potential as drug delivery vehicles because they are very porous, allowing small
drug molecules like the anticancer drug cisplatin to be loaded into the interior spaces
and slowly released. The surface can also be modified so that a drug can be attached,
creating much potential for carbon nanohorns to act as double reservoirs. They can
combine methods for treating both inflammation and tumors. Research has shown that
nanohorns can release a bioactive drug over a longer period of time, making it very
useful for treatment. CNHs tend to aggregate inside tumors, which would allow the drug
to empty into the tumor directly over time (8). The surface of the nanohorns can be
modified to allow the structure to become more water soluble so it can be dissolved in
the blood and removed from the human body after use. Fluorescent molecules can also
be attached to the nanohorns, allowing them to be used for imaging as well (6). This
combination of properties makes carbon nanohorns very suitable candidates for use in
the theranostic field.

Figure 2. Structure of a carbon nanohorn (17).
In an experiment with mice, researchers injected modified CNHs into non-small
cell lung cancer tumors and saw significantly retarded tumor growth. They also
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observed the migration of these CNHs to the adjacent axillary lymph node—a major site
of breast cancer metastasis. Due to these findings, researchers believe that these
modified water-dispersed CNHs have the potential to be excellent drug carriers for
chemotherapy, specifically against cancers that include lymph node metastasis (7).
Carbon nanomaterials are proven to have many advantages in the field of
theranostics and nanomedicine. They continue to be the subjects of much research as
they have their novel properties explored more in depth. CNMs seem to have much
potential to help improve upon cancer therapy and diagnostics and may aide in making
treatments more personalized as well. Hopefully carbon nanomaterials will fulfill their
potential and become the major theranostic agents in the future.

INTRODUCTION TO PROJECT
As noted above, carbon nanomaterials have much potential in bioimaging and
theranostic delivery for cancer treatment. The goal of this project was to prepare a novel
carbon nano-onion platinum nanomaterial and test its cytotoxicity and potential for use
in cancer therapy. This was achieved by attaching cisplatin to the outer shell of the
CNOs and then testing it against U87 glioblastoma cells.

BACKGROUND
What are Carbon Nano-Onions?
Among many other types of carbon nanomaterials, carbon nano-onions (CNOs)
(Figure 3) are particular CNMs of interest because they have shown to be less toxic
than other CNMs and have the ability to be internalized by cells. Solubility of the CNOs
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is greatly increased when their outer surface is functionalized, and functionalization
increases their potential for theranostic application. Carbon nano-onions (CNOs) are
characterized by a closed carbon shell and multiple layers which resemble an onion.
The outer surface can be functionalized to make the material more soluble, which
allows CNOs to be used for bioimaging and show potential for use in cancer therapy.
CNOs have already proven effective as agents for cellular imaging. Fluorescent
compounds can readily be added to the surface of the CNOs and visualized using
fluorescence microscopy. The CNOs are readily taken up and can be localized to
specific compartments of cells, which makes them well suited for use in bioimaging (9).
CNOs are also useful as drug carriers and delivery vehicles. They are small enough to
travel well through the circulatory system and are effectively taken up by cells. Due to
their small size, they are able to access a wide range of biological targets. Some
biomolecules can also be attached to the surface of the CNOs, which broadens their
potential as intracellular carriers even more (9). In the future, the hope is to be able to
attach a cytotoxic drug, such as cisplatin, which can be taken up by cancer cells and
destroy them more effectively.

Figure 3. Structure and microscopic view of
carbon nano-onions (16).
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Cisplatin in Chemotherapy
Chemotherapy is a treatment that uses powerful chemicals to destroy rapidly
dividing cells in the body. It is used in the treatment of cancer due to the fact that cancer
cells grow and multiply much more quickly than most other cells in the body.
Unfortunately, current chemotherapy treatments affect the whole body, destroying many
good cells along with the cancerous cells. Finding a way to utilize chemotherapy in a
more localized area and decrease the side effects that accompany the destruction of
healthy cells would be a major step forward in the treatment of cancer.
Cisplatin is a common drug used in chemotherapy. It was the first big
chemotherapy drug to be used and is sometimes referred to as the “penicillin of cancer”
(11). Cisplatin operates by forming a platinum complex inside a cell which binds DNA.
When the DNA is crosslinked in this manner, the cell is signaled to undergo apoptosis
and the cell dies. Unfortunately, cisplatin can affect the DNA of other cells in the body,
which may lead to harsh side effects. Though it is one of the oldest chemotherapy
drugs, is still widely used in treatment today either as the main drug or as part of a
combination regimen (11). Carbon nanomaterials are now being explored as potential
drug carriers for cisplatin. Many other
new therapies using cisplatin continue
to be explored with the goal of treating
a more localized area to help reduce
the harmful side effects that take such
a toll on the body.
Figure 4. Chemical structure of cisplatin.
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METHODS
Preparation of Oxidized-CNOs (ox-CNOs)
To prepare the oxidized carbon nano-onions, 0.04 g of CNOs were added to a 50
mL round bottom flask, along with 30 mL of 3M nitric acid. The reaction was then
refluxed for 48 hours. After 48 hours, the reaction was removed from heat and allowed
to cool. Next, the reaction was filtered using vacuum filtration to obtain the product. A
Millipore 0.20 µm nylon membrane filter was weighed and then placed in the filter
funnel. The reaction was diluted with deionized water and then poured through the filter.
After filtering, the ox-CNOs were washed 3 times each with deionized water, methanol,
and acetone. After washing, ox-CNOs were placed on a watch glass and allowed to air
dry overnight.

Figure 5. Reaction to prepare ox-CNOs from CNOs in 3M nitric acid.
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Preparation of Fluorescent-CNOs (fluoro-CNOs)
To prepare the fluorescent-CNOs, 0.015 g ox-CNOs and dry tetrahydrofuran
(THF)/dimethylformamide (DMF) (2:1 ratio) were added to a Teflon beaker and
ultrasonicated for 20 minutes at 37 kHz. The mixture was then added to a 50 mL round
bottom flask and deoxygenated under nitrogen. 4-dimethylaminopyridine (DMAP), 0.050
g, 0.050 g of N-hydroxysuccinimide (NHS), 0.080 g of 1-Ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC-HCl), and 0.040 g of fluoresceinamine were
added to the flask. The mixture was briefly sonicated and then refluxed under nitrogen
for 4 days.
After 4 days, the reaction was stopped and allowed to cool. The product was
obtained by using vacuum filtration. A 0.20 µm nylon membrane filter was weighed and
then placed in the filter funnel on the vacuum. After filtering the original reaction mixture,
the product was washed 3 times with both THF and acetone. Figure 6 shows the
addition of fluoresceinamine to the ox-CNOs.

Figure 6. Reaction to prepare fluorescent-CNOs.
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Preparation of cisplatin-CNOs (CNO-Pt)
To prepare the platinum CNOs, 0.015 g ox-CNOs and dry THF/DMF (2:1 ratio) were
added to a Teflon beaker and ultrasonicated for 20 minutes at 37 kHz. The mixture was
then added to a 50 mL round bottom flask and deoxygenated under nitrogen. DMAP,
0.050 g, 0.050 g of NHS, 0.080 g of EDC-HCl, and 0.036 g of cisplatin were added to
the flask. The mixture was briefly sonicated and then refluxed under nitrogen for 4 days.
After 4 days, the reaction was stopped and allowed to cool. When cooled, vacuum
filtration was performed to obtain the product. Again, a nylon filter was used to collect
the product. After filtering the original reaction mixture, the product was washed 3 times
with both THF and acetone. Figure 7 shows the addition of cisplatin to the ox-CNOs.
The complete reaction to prepare fluoro-CNOs is shown using functional groups in
Figure 8. The complete reaction for the preparation of CNO-Pt is also shown using
functional groups in Figure 9.

Figure 7. Reaction to prepare CNO-Pt.
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Figure 8. Complete reaction to prepare
fluorescent-CNOs.

Figure 9. Complete reaction to prepare CNO-Pt.

CHARACTERIZATION AND RESULTS
Ultraviolet-Visible Spectroscopy
Ultraviolet-Visible (UV-Vis) spectroscopy is a useful tool to measure the
absorbance of light by a sample. The perceived color of a molecule on either the
ultraviolet or visible spectrum is indicated by a particular absorbance number. Energy
from the different wavelengths of light is absorbed by molecules and can possibly excite
electrons into higher energy orbitals. Easily excited electrons can absorb longer
wavelengths of light. In UV-Vis, specific wavelengths of light are passed through a
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solution and the absorbance of light is analyzed. The solution absorbs the light and is
read and recorded by a detector (12).
Ox-CNOs (Figure 10) have characteristic peak near 280 nm. Fluoresceinamine
has a characteristic peak near 485 nm, as seen in Figure 11. The UV-Vis spectrum of
fluoro-CNOs is seen in Figure 12. The coupling of the ox-CNOs and fluoresceinamine is
represented by the peak near 280 nm (characteristic of the ox-CNOs) and the new peak
near 520 nm (characteristic of fluoresceinamine). Comparing the spectra, we can see
that the fluoresceinamine was successfully coupled to the ox-CNOs to produce the
fluoro-CNOs.
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Figure 10. UV-Vis Spectrum of ox-CNOs in MeOH.
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Figure 11. UV/Vis spectrum of fluoresceinamine in MeOH.
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Infrared Spectroscopy
Infrared (IR) spectroscopy is another useful tool in determining the structure of
molecules. Different functional groups can absorb infrared radiation at different
wavelengths based on their shape. As energy is absorbed by a functional group, it
bends or stretches. The IR spectrometer creates a graph which records the
wavenumber and transmittance of the stretch or bend (13).
The ox-CNOs have a peak near 1680 cm-1 that is characteristic of the carboxylic
acids attached to the outer shell of the CNOs. Fluoro-CNOs displayed a new band near
1580 cm-1 which is characteristic of the attachment of fluoresceinamine as seen in
Figure 13. This same set of peaks can be seen in the attachment of the Pt of cisplatin
as observed in Figure 14. These peaks confirm the presence of the materials attached
to the ox-CNO material.

75

p-CNO

%T

70
65
60
55
ox-CNO

%T

40

30

20
70 Fluoro-CNO

%T

60

50

40
4000

3500

3000

2500

2000

1500

1000

500

Wavenumbers (cm-1)

Figure 13. Overlay of the IR Spectra of p-CNO, ox-CNO, and fluoro-CNO
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Figure 14. Overlay of the IR Spectra of p-CNO, ox-CNO, and CNO-Pt
Fluorescence Microscopy
Fluorescence microscopy uses fluorescence or phosphorescence to analyze the
properties of a substance instead of reflection and absorption. Fluorescence can be
observed in some substances that absorb light or electromagnetic radiation and in turn
emit light. It is very beneficial because it makes it possible to visibly see specific parts of
some substances (14).
Fluoro-CNOs were analyzed under regular light and at excitatory wavelengths to
view fluorescence. Fluoresceinamine is excited and fluoresces at a lmax of 496 nm. At
nonexcitatory wavelengths, the fluoro-CNOs were seen as black spots only (Figure 15).
Under the excitatory wavelengths of light, parts of the fluoro-CNOs were visibly
fluorescing (Figure 16), confirming the attachment of fluoresceinamine to the outer CNO
shell.
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Figure 15. Fluoro-CNOs under white light.

Figure 16. Fluoro-CNOs under UV light.
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CELL TESTING
Procedure
An in-vitro cytotoxicity assay was performed using Alamar Blue in order to
measure cell viability. Alamar blue is a cell permeable reagent that contains blue
fluorescent indicator dye called resazurin. This reagent is useful because it is non-toxic
to cells, unlike the more commonly used MTT assay reagents. Resazurin changes
colors in response to a metabolic reduction in cells and the reduced form fluoresces
proportionally to the number of living cells present (15). Therefore, it can quantitatively
measure cell viability in each well.
In this Alamar blue assay, U87 glioblastoma cells were plated onto a 96 well
plate and allowed to grow for approximately 24 hours. Once cultured, the cells were
treated with various concentrations of each of the ox-CNOs, fluoro-CNOs, and platinumCNOs. The plate was incubated for 24 hours and then placed on a plate reader to
determine cell viability.

Figure 17. Alamar blue assay after 24 hours.
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Results
As mentioned above, the Alamar Blue assay was used to test cell viability of U87
cells after treatment with the various CNOs. Ox-CNOs and fluoro-CNOs were tested
against the cells each at a concentration of 10 µg/mL. Percent viability of the ox-CNOs
and fluoro-CNOs was approximately 50% (Figure 18). The platinum-CNOs were tested
against the cells at concentrations of 1, 5, and 10 µg/mL. Percent viability of the
platinum-CNOs was near 75% (Figure 19).

Figure 18. Results from testing cell viability of CNOs.
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Figure 19. Results from testing cell viability of CNO-Pt.

CONCLUSIONS
In conclusion, CNOs were able to be successfully oxidized and functionalized
with fluoresceinamine. This was confirmed by UV-Vis spectroscopy, IR spectroscopy,
and fluorescence microscopy. UV-Vis confirmed the coupling of fluoresceinamine to the
ox-CNOs to produce fluoro-CNOs, represented by the peak seen at 520 nm on the
spectra. IR spectroscopy showed the characteristic peak of fluoresceinamine at 1580
cm-1 after coupling to the ox-CNOs. Fluorescence microscopy further confirmed the
attachment of the fluoresceinamine as it could be seen visibly fluorescing under
excitatory wavelengths. The novel CNO-Pt nanomaterial was also successfully
prepared and characterized by IR spectroscopy. After running the IR on the CNO-Pt
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nanomaterial, the spectrum showed an expected peak near 1580 cm-1 which confirmed
the attachment of cisplatin to the ox-CNOs. Ox-CNOs and fluoro-CNOs tested against
U87 glioblastoma cells showed approximately 50% cell viability after 24 hours. The
platinum-CNOs showed near 75% viability at all concentrations.
The CNO-Pt material appeared to have killed near 25% of the U87 cancer cells
at each concentration after only 24 hours. As previously mentioned, some carbon
nanomaterials have been shown to stay in circulation and continue releasing their drug
for an extended period of time. This data suggests that this novel CNO-Pt material could
be a potential candidate for use as a theranostic delivery vehicle in cancer therapy.
Further experimentation will help to provide more conclusive data on this CNO-Pt
material and how useful it might be in nanomedicine.

FUTURE WORK
Carbon nano-onions, along with other types of carbon nanomaterials, appear to
have much promise for use as theranostic agents. The CNO-Pt material shows
potential, but more experimentation and data will be required to conclude their full
capabilities as theranostic agents. In the future, more data will be collected through the
use of Raman spectroscopy. A platinum analysis will be conducted using ICP
(Inductively Coupled Plasma) spectroscopy to ensure the incorporation of the platinum
in the CNO-Pt material. An MTT assay will be performed to assess cytotoxicity of the
CNO materials in hopes of gaining more data to support the potential for use in the field
of theranostics.

24

REFERENCES
1. Wilson, Damien Jonas. “What Is Theranostics?” News, 14 Nov. 2018, www.newsmedical.net/health/What-is-Theranostics.aspx.
2. “What Is Nanomedicine?” Center for Nanomedicine, cnm-hopkins.org/what-is-nanomedicine/.
3. Theek, Benjamin, et al. “The Theranostic Path to Personalized Nanomedicine.” Clinical and
Translational Imaging, U.S. National Library of Medicine, 1 Feb. 2014,
www.ncbi.nlm.nih.gov/pmc/articles/PMC4031631/.
4. Ren, Guoqiang. “Carbon Nanotubes.” Encyclopædia Britannica, Encyclopædia Britannica,
Inc., 16 Nov. 2018, www.britannica.com/science/carbon-nanotube.
5. Madani, Seyed Yazdan, et al. “A New Era of Cancer Treatment: Carbon Nanotubes as Drug
Delivery Tools.” International Journal of Nanomedicine, Dove Medical Press, 2011,
www.ncbi.nlm.nih.gov/pmc/articles/PMC3230565/.
6. “Carbon Nanohorn.” Carbon Nanohorn - An Overview,
www.sciencedirect.com/topics/chemistry/carbon-nanohorn.
7. “Carbon Nanohorn.” Carbon Nanohorn - an Overview | ScienceDirect Topics,
www.sciencedirect.com/topics/chemistry/carbon-nanohorn.
8. Matsumura, Sachiko et al. “Ultrastructural localization of intravenously injected carbon
nanohorns in tumor.” International Journal of Nanomedicine vol. 9 3499-508. 23 Jul.
2014, doi:10.2147/IJN.S62688
9. Bartelmess, Juergen, and Silvia Giordani. “Carbon Nano-Onions (Multi-Layer Fullerenes):
Chemistry and Applications.” Beilstein Journal of Nanotechnology, Beilstein-Institut, 4
Nov. 2014, www.beilstein-journals.org/bjnano/articles/5/207.
10. d’Amora, Marta, and Rosaria Brescia. “Carbon Nano-Onions as Non-Cytotoxic Carriers for
Cellular Uptake of Glycopeptides and Proteins.” MDPI, Multidisciplinary Digital
Publishing Institute, 25 July 2019, www.mdpi.com/2079-4991/9/8/1069/htm.

25

11. “Information on the Chemotherapy Medication Cisplatin.” Cisplatin, www.cisplatin.org/.
12. Reusch, William. “Visible and Ultraviolet Spectroscopy.” UV-Visible Spectroscopy, 5 May
2013, www2.chemistry.msu.edu/faculty/reusch/virttxtjml/spectrpy/uv-vis/spectrum.htm.
13. Hurst, George Samuel, and John Oliver Stoner. “Infrared Spectroscopy.” Encyclopædia
Britannica, Encyclopædia Britannica, Inc., 8 June 2018,
www.britannica.com/science/spectroscopy/Infrared-spectroscopy.
14. “Fluorescence Microscopy.” Fluorescence Microscopy - an Overview | ScienceDirect Topics,
www.sciencedirect.com/topics/materials-science/fluorescence-microscopy.
15. Bio-Rad. “What Is AlamarBlue?: Bio-Rad.” Bio, www.bio-rad-antibodies.com/alamarbluecell-viability-assay-resazurin.html.
16. Bourassa, Daniel & Kerna, Nicholas. (2018). “Will Nanocarbon Onion-Like Fullerenes
(NOLFs) Play a Decisive Role in the Future of Molecular Medicine? Part 1.” Foundation
in Fullerenes: Theoretical Application of NOLFs in the Quantum Cell.
17. Serban, Bogdan-Catalin & Bumbac, Marius & Buiu, Octavian & Cobianu, Cornel &
Brezeanu, Mihai & Nicolescu, Cristina Mihaela. (2018). “CARBON NANOHORNS AND
THEIR NANOCOMPOSITES: SYNTHESIS, PROPERTIES AND APPLICATIONS. A
CONCISE REVIEW.” Annals of the Academy of Romanian Scientists Series on Science
and Technology of Information. Volume 11, page 5.

26

